|
Company:
|
VIKING THERAPEUTICS, INC. (VKTX)
|
|
Form Type:
|
4/A
|
|
Filing Date:
|
8/28/2020
|
|
CIK:
|
0001607678
|
|
Address:
|
9920 PACIFIC HEIGHTS BLVD, SUITE 350
|
|
City, State, Zip:
|
SAN DIEGO, California 92121
|
|
Telephone:
|
858-704-4660
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$16.65
|
Change:
-0.68 (-3.92%)
|
Trade Time:
Mar 31
|
Market Cap:
$1.31B
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage biopharmaceutical company focused on the development of
novel, first-in-class or best-in-class therapies for metabolic and endocrine
disorders.
Our lead clinical program's drug candidate, VK2809, is an orally available,
tissue and receptor-subtype selective agonist of the thyroid hormone receptor
beta, or TRß. In November 2019, we initiated the VOYAGE study, a Phase 2b
clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic
steatohepatitis, or NASH.
The VOYAGE study is a randomized, double-blind, placebo-controlled, multicenter
trial designed to assess the efficacy, safety and tolerability of VK2809 in
patients with biopsy-confirmed NASH and fibrosis ranging from stages F1 to F3.
|
|
|
|